These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 8217066)

  • 21. [Residual symptoms after a treated major depressive disorder: in practice ambulatory observatory carried out of city].
    Mouchabac S; Ferreri M; Cabanac F; Bitton M
    Encephale; 2003; 29(5):438-44. PubMed ID: 14615693
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma free 3-methoxy-4-hydroxyphenylglycol predicts response to fluoxetine.
    Ko HC; Lu RB; Shiah IS; Hwang CC
    Biol Psychiatry; 1997 Apr; 41(7):774-81. PubMed ID: 9084896
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effectiveness of carbamazepine in unipolar depression: a double-blind, randomized, placebo-controlled study.
    Zhang ZJ; Tan QR; Tong Y; Li Q; Kang WH; Zhen XC; Post RM
    J Affect Disord; 2008 Jul; 109(1-2):91-7. PubMed ID: 18093662
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Crocus sativus L. in the treatment of mild to moderate depression: a double-blind, randomized and placebo-controlled trial.
    Akhondzadeh S; Tahmacebi-Pour N; Noorbala AA; Amini H; Fallah-Pour H; Jamshidi AH; Khani M
    Phytother Res; 2005 Feb; 19(2):148-51. PubMed ID: 15852492
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Maprotiline versus fluvoxamine: comparison of their effects on the hypothalamo-hypophyseal-thyroid axis].
    De Mendonça Lima CA; Vandel S; Bonin B; Bechtel P; Carron R
    Encephale; 1997; 23(1):48-55. PubMed ID: 9172968
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety.
    Fawcett J; Barkin RL
    J Clin Psychiatry; 1998 Mar; 59(3):123-7. PubMed ID: 9541155
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fluoxetine treatment of dysthymia in the elderly.
    Nobler MS; Devanand DP; Kim MK; Fitzsimons LM; Singer TM; Turret N; Sackeim HA; Roose SP
    J Clin Psychiatry; 1996 Jun; 57(6):254-6. PubMed ID: 8666563
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Duloxetine in the treatment of Major Depressive Disorder: a comparison of efficacy in patients with and without melancholic features.
    Mallinckrodt CH; Watkin JG; Liu C; Wohlreich MM; Raskin J
    BMC Psychiatry; 2005 Jan; 5():1. PubMed ID: 15631624
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Maprotiline in pain-depression.
    Lindsay PG; Olsen RB
    J Clin Psychiatry; 1985 Jun; 46(6):226-8. PubMed ID: 3888970
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The Eppendorf Mood and Motivation Scale as assessment procedure in the clinical evaluation of an antidepressive agent].
    Binz U; Wendt G
    Fortschr Med; 1982 Dec; 100(45):2111-7. PubMed ID: 6757074
    [No Abstract]   [Full Text] [Related]  

  • 31. Extended-release venlafaxine in relapse prevention for patients with major depressive disorder.
    Simon JS; Aguiar LM; Kunz NR; Lei D
    J Psychiatr Res; 2004; 38(3):249-57. PubMed ID: 15003430
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A randomized controlled trail of maprotiline treatment of depressive disorder].
    Lei M
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1991 Oct; 24(5):265-7, 316. PubMed ID: 1752175
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response to treatment in minor and major depression: results of a double-blind comparative study with paroxetine and maprotiline.
    Szegedi A; Wetzel H; Angersbach D; Philipp M; Benkert O
    J Affect Disord; 1997 Sep; 45(3):167-78. PubMed ID: 9298430
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Biochemical, pharmacologic and psychophysiologic studies for the optimization of drug therapy in depressive illnesses].
    Gaertner HJ; Giedke H; Breyer-Pfaff U
    Nervenarzt; 1984 Mar; 55(3):133-6. PubMed ID: 6717696
    [No Abstract]   [Full Text] [Related]  

  • 35. Treatment of depression with maprotiline hydrochloride: multicenter evaluation of efficacy and tolerability.
    Clin Ther; 1983; 5(4):377-84. PubMed ID: 6347381
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A clinical test of noradrenergic involvement in the therapeutic mode of action of an experimental antidepressant.
    Katz RJ; Lott M; Landau P; Waldmeier P
    Biol Psychiatry; 1993 Feb; 33(4):261-6. PubMed ID: 8471679
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recovery from depression: triggers and time patterns.
    Parker G
    Aust N Z J Psychiatry; 1996 Aug; 30(4):442-4. PubMed ID: 8887691
    [No Abstract]   [Full Text] [Related]  

  • 38. Long term treatment with oxaprotiline in patients with major depression.
    Katz RJ
    Prog Neuropsychopharmacol Biol Psychiatry; 1989; 13(6):875-83. PubMed ID: 2813805
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A controlled study of the efficacy and safety of mianserin and maprotiline in outpatients with major depression.
    Möller HJ; Riehl T; Dietzfelbinger T; Wernicke T
    Int Clin Psychopharmacol; 1991; 6(3):179-92. PubMed ID: 1806624
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Levoprotiline--function regulator of food and satiety centres?
    Faltus F; Janecková E
    Act Nerv Super (Praha); 1989 Dec; 31(4):282-3. PubMed ID: 2638111
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.